Customer:
VIOBAC
Prevents catheter associated infections
Catheter-associated urinary tract infections (CAUTI) have been reported as the most common hospital acquired infection in the world being responsible for up to 40% of all hospital infections, with more than 1 million cases per year in the US alone.
Approximately 25% of hospitalized patients will undergo urinary catheterization, and nearly 30% of these will develop CAUTI.
VIOBAC has invented a solution - BaLu™ - to the problem
BaLu™ is an innovative UV light solution designed to reduce catheter-associated infections. The solution is a click-on device developed to prevent bacteria from getting into the patients urinary tract system - and will thereby prevent unnecessary urinary tract infections from happening when using a catheter.
VIOBAC has been voted the best university startup in the world within the health category (goal 3) with incorporation of the UN’s 17 Sustainable Development Goals, 2019.
VIOBAC has been chosen as one of the 10 selected participants for Nordic Health Tech Talents (NHTT) 2019 hosted by Venture Cup. VIOBAC was named as one of the winners of the 2019 EIT Health Scandinavia Headstart Award.
From idea to innovation
A mission where technology and societal value come together – and where innovation truly makes a difference. Prevas has contributed with:
- Hardware
- Software
- Mechanics
- Project Management
- Quality Assurance
Our expertise
Project management, Embedded Systems, Mechanics, Hardware and Software Design & Development, Quality Assurance
Contact us
Henrik Møller, Prevas A/S, e-mail
.png)
Related cases
-
VIOBAC
Prevents catheter associated infections
-
Nipro Medical Europe
Prevas UX/UI-expertise helps Nipro choose the right solutions within new design concept
-
Gradientech
Ultra-fast diagnostics system can save lives and counteract antibiotic resistance
-
4Life Solutions
Clean drinking water in four hours
Follow us on social media
